isonicotinic acid but-2-enylidenehydrazide | 7007-96-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: isonicotinic acid but-2-enylidenehydrazide
• 英文别名: Isonicotinsaeure-but-2-enylidenhydrazid；crotonaldehyde isonicotinoylhydrazone；Crotoniazide；N-[(E)-[(E)-but-2-enylidene]amino]pyridine-4-carboxamide
• CAS: 7007-96-7
• 化学式: C₁₀H₁₁N₃O
• 分子量: 189.217
• InChiKey: YLWYNCPRXFCNLQ-WYIUXTECSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  异烟肼 、 巴豆醛 在 苯 作用下， 生成 isonicotinic acid but-2-enylidenehydrazide
  参考文献：
  名称：

  Lespagnol et al., Bulletin de la Societe de Pharmacie de Lille, 1955, p. 30,32

  摘要：

  DOI：

文献信息

• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Process for producing 1-acyl-2-pyrazoline derivatives
  申请人：MITSUI TOATSU CHEMICALS, Inc.

  公开号：EP0322691A1

  公开（公告）日：1989-07-05

  1-Acyl-2-pyrazoline derivatives represented by the formula where R¹ denotes a hydrogen atom, pyridyl group, pyrazinyl group, alkyl group, aryl group, or alkoxy group; and R², R³, and R⁴ independently denote a hydrogen atom, furyl group, pyridyl group, alkyl group, or aryl group, are produced by cyclizing by heating an acylhydrazone derivative represented by the formula where R¹, R², R³, and R⁴ are defined as above, to produce compounds having useful anti-cerebral edema activity.

  1-酰基-2-吡唑啉衍生物，由式表示 式中 R¹表示氢原子、吡啶基、吡嗪基、烷基、芳基或烷氧基；R²、R³和R⁴独立地表示氢原子、糠基、吡啶基、烷基或芳基，通过加热环化由式表示的酰基腙衍生物而制得。 其中 R¹、R²、R³ 和 R⁴ 的定义同上，从而制得具有有效抗脑水肿活性的化合物。
• APPLICATION OF AND PREPARATION METHOD FOR CATIONIC POLYMER MODIFIED BY FLUORINE-CONTAINING COMPOUND AS DRUG CARRIER
  申请人：Soochow University

  公开号：EP4095162A1

  公开（公告）日：2022-11-30

  The invention provides a fluorinated chitosan derivative as a drug carrier, which has the following structure: a fluorine-containing compound covalently attached to the backbone of chitosan. The chitosan has a molecular weight in the range of 1000-5000000, a degree of deacetylation of not less than 55%, and a viscosity in the range of 25-1000 cps. The fluorine-containing compound is a fluorine-containing aliphatic chain shown by the following chemical formula (I) or an aromatic ring with functional groups shown by the following formula (II) wherein Ri is halogen (fluorine, chlorine, bromine, iodine), or a halogen-substituted alkane, cycloalkane, aldehyde group, carboxyl group, alkenyl group, alkynyl group, hydroxyl group, sulfonyl chloride, sulfonic acid bond or mercapto group, for interacting with a primary amino group. The compounds of the present invention can be universally bound to a variety of drugs to promote drug absorption and bioavailability, and reduce toxicity.

  本发明提供了一种作为药物载体的氟化壳聚糖衍生物，其结构如下：一种含氟化合物共价连接到壳聚糖的骨架上。壳聚糖的分子量在 1000-5000000 之间，脱乙酰度不低于 55%，粘度在 25-1000 cps 之间。含氟化合物是由以下化学式（I）表示的含氟脂肪族链 或带有下式（II）所示官能团的芳香环 其中 Ri 为卤素（氟、氯、溴、碘），或卤素取代的烷基、环烷基、醛基、羧基、 烯基、炔基、羟基、磺酰氯、磺酸键或巯基，用于与伯氨基相互作用。本发明的化合物可与多种药物普遍结合，以促进药物的吸收和生物利用度，并降低毒性。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。
• Wound closure systems for reducing surgical site infections comprising incision drapes filled with releasable antimicrobial agents
  申请人：Ethicon, Inc.

  公开号：US11452641B2

  公开（公告）日：2022-09-27

  A surgical incision drape, comprises a flexible substantially flat areal substrate having an upper side and an opposing tissue-facing side, having a longitudinal axis and a pressure sensitive adhesive disposed on the tissue-facing side; at least one hollow microtubular compartment containing a flowable medical agent, said hollow microtubular compartment positioned to intersect the longitudinal axis and embedded into the substrate or positioned on the substrate.

  一种手术切口敷料，包括一个柔性大体平坦的基底，基底有一个上侧和一个相对的面向组织的侧，基底有一个纵轴，面向组织的侧上有一个压敏粘合剂；至少一个中空微管隔室，内装可流动的医用制剂，所述中空微管隔室的位置与纵轴相交，并嵌入基底或设置在基底上。